In fact, in 2016, by combining morphology and genetic alterations, the WHO updated their guidelines, leading to the emergence of two entities based on the mutational status of the IDH gene: IDH wild-type and IDH mutated GBM [73]. The gene discussed is IDH1; the disease is glioblastoma.